Marta Canela Capdevila

Ms. Marta Canela Capdevila

orcid

Research Focus & Metrics

Representative Publications

View All Publications
6 December 2023 in Clinical Nutrition
Verified
Journal Article
Open access
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
HCHelena Castañé
Helena Castañé
CMCristian Martínez-Navidad
Cristian Martínez-Navidad
CPCristina Placed-Gallego
Cristina Placed-Gallego
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
Jorge JovenJorge Joven
Jorge Joven
The relationship between lipid mediators and severe obesity remains unclear. Our study investigates the impact of severe obesity on plasma concentrations of oxylipins and fatty acids and explores the consequences of weight loss. In the clinical trial identifier NCT05554224 study, 116 patients with severe obesity and 63 overweight/obese healthy controls matched for age and sex (≈2:1) provided plasma. To assess the effect of surgically induced weight loss, we requested paired plasma samples from 44 patients undergoing laparoscopic sleeve gastrectomy one year after the procedure. Oxylipins were measured using ultra-high-pressure liquid chromatography coupled to a triple quadrupole mass spectrometer via semi-targeted lipidomics. Cytokines and markers of interorgan crosstalk were measured using enzyme-linked immunosorbent assays. We observed significantly elevated levels of circulating fatty acids and oxylipins in patients with severe obesity compared to their metabolically healthier overweight/obese counterparts. Our findings indicated that sex and liver disease were not confounding factors, but we observed weak correlations in plasma with circulating adipokines, suggesting the influence of adipose tissue. Importantly, while weight loss restored the balance in circulating fatty acids, it did not fully normalize the oxylipin profile. Before surgery, oxylipins derived from lipoxygenase activity, such as 12-HETE, 11-HDoHE, 14-HDoHE, and 12-HEPE, were predominant. However, one year following laparoscopic sleeve gastrectomy, we observed a complex shift in the oxylipin profile, favoring species from the cyclooxygenase pathway, particularly proinflammatory prostanoids like TXB2, PGE2, PGD2, and 12-HHTrE. This transformation appears to be linked to a reduction in adiposity, underscoring the role of lipid turnover in the development of metabolic disorders associated with severe obesity. Despite the reduction in fatty acid levels associated with weight loss, the oxylipin profile shifts towards a predominance of more proinflammatory species. These observations underscore the significance of seeking mechanistic approaches to address severe obesity and emphasize the importance of closely monitoring the metabolic adaptations after weight loss.

1 July 2024 in Viruses
Verified
Journal Article
Open access
PDF file
Simona Iftimie IftimieSimona Iftimie Iftimie
Simona Iftimie Iftimie
XGXavier Gabaldó-Barrios
Xavier Gabaldó-Barrios
JPJoan Penadés-Nadal
Joan Penadés-Nadal
MCMarta Canela Capdevila
Marta Canela Capdevila
RPRubén Piñana
Rubén Piñana
Jorge JovenJorge Joven
Jorge Joven
Acute respiratory tract infections, including influenza A (FluA), respiratory syncytial virus (RSV) infection, and COVID-19, can aggravate to levels requiring hospitalization, increasing morbidity and mortality. Identifying biomarkers for an accurate diagnosis and prognosis of these infections is a clinical need. We performed a cross-sectional study aimed to investigate the changes in circulating levels of arachidonic acid, interleukin 6 (IL-6), and C-reactive protein (CRP) in patients with FluA, RSV, or COVID-19, and to analyze the potential of these parameters as diagnosis or prognosis biomarkers. We analyzed serum samples from 172 FluA, 80 RSV, and 217 COVID-19 patients, and 104 healthy volunteers. Individuals with lung viral diseases showed reduced arachidonic acid concentrations compared to healthy people, with these differences being most pronounced in the order COVID-19 > RSV > FluA. Conversely, IL-6 and CRP levels were elevated across diseases, with IL-6 emerging as the most promising diagnostic biomarker, with areas under the curve (AUC) of the receiver operating characteristics plot higher than 0.85 and surpassing arachidonic acid and CRP. Moreover, IL-6 displayed notable efficacy in distinguishing between FluA patients who survived and those who did not (AUC = 0.80). These findings may provide useful tools for diagnosing and monitoring the severity of acute viral respiratory tract infections, ultimately improving patient outcomes.

26 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
JAJuan Manuel Jiménez Aguilar
Juan Manuel Jiménez Aguilar
MCMarta Canela Capdevila
Marta Canela Capdevila
RGRaquel García-Pablo
Raquel García-Pablo
HCHelena Castañé
Helena Castañé
Meritxell ArenasMeritxell Arenas
Meritxell Arenas
Background/Objectives: The management of early breast cancer (BC) includes surgery, followed by adjuvant radiotherapy, chemotherapy, hormone therapy, or immunotherapy. However, the influence of these interventions in metabolic reprogramming remains unknown. This study explored alterations in the plasma metabolome of BC patients following distinct treatments to deepen our understanding of BC pathophysiology, outcomes, and the identification of potential biomarkers. Methods: We included 52 women diagnosed with BC and candidates for surgery as primary oncological treatment. Blood samples were collected at diagnosis, two weeks post-surgery, and one month post-radiotherapy. Plasma samples from 49 healthy women served as controls. Targeted metabolomics assessed 74 metabolites spanning carbohydrates, amino acids, lipids, nucleotide pathways, energy metabolism, and xenobiotic biodegradation. Results: Before treatment, the BC patients exhibited notable changes in carbohydrate, nucleotide, lipid, and amino acid metabolism. We noticed a gradual restoration of specific metabolite levels (hypoxanthine, 3-phosphoglyceric acid, xylonic acid, and maltose) throughout different treatments, suggesting a normalization of the nucleotide and carbohydrate metabolic pathways. Moreover, we observed increased dodecanoic acid concentrations, a metabolite associated with cancer protection. These variations distinguished patients from controls with high specificity and sensitivity. Conclusions: Our preliminary study suggests that oncological treatments modify the metabolism of patients towards a favorable profile with a decrease in the pathways that favor cell proliferation and an increase in the levels of anticancer molecules. These findings emphasize the pivotal role of metabolomics in recognizing the biological pathways influenced by each cancer treatment and the resulting metabolic consequences. Furthermore, it aids in identifying potential biomarkers for disease onset and progression.

24 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
MMMauricio Murcia-Mejia
Mauricio Murcia-Mejia
MCMarta Canela Capdevila
Marta Canela Capdevila
RGRaquel García-Pablo
Raquel García-Pablo
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
JAJuan Manuel Jiménez Aguilar
Juan Manuel Jiménez Aguilar
Jorge JovenJorge Joven
Jorge Joven
Lung cancer is the leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for over 85% of cases and poor prognosis in advanced stages. This study explored shifts in circulating metabolite levels in NSCLC patients versus healthy controls and examined the effects of conventionally fractionated radiation therapy (CFRT) and stereotactic body radiation therapy (SBRT). We enrolled 91 NSCLC patients (38 CFRT and 53 SBRT) and 40 healthy controls. Plasma metabolite levels were assessed using semi-targeted metabolomics, revealing 32 elevated and 18 reduced metabolites in patients. Key discriminatory metabolites included ethylmalonic acid, maltose, 3-phosphoglyceric acid, taurine, glutamic acid, glycocolic acid, and d-arabinose, with a combined Receiver Operating Characteristics curve indicating perfect discrimination between patients and controls. CFRT and SBRT affected different metabolites, but both changes suggested a partial normalization of energy and amino acid metabolism pathways. In conclusion, metabolomics identified distinct metabolic signatures in NSCLC patients with potential as diagnostic biomarkers. The differing metabolic responses to CFRT and SBRT reflect their unique therapeutic impacts, underscoring the utility of this technique in enhancing NSCLC diagnosis and treatment monitoring.

26 February 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
VCVicente Cambra-Cortés
Vicente Cambra-Cortés
RGRaquel García-Pablo
Raquel García-Pablo
MCMarta Canela Capdevila
Marta Canela Capdevila
RBRocío Benavides-Villarreal
Rocío Benavides-Villarreal
Meritxell ArenasMeritxell Arenas
Meritxell Arenas
Research on biomarkers reflecting tumor biology and systemic metabolism is crucial for improving the accuracy and personalization of breast cancer (BC) prognosis. We investigated circulating dodecanoic acid in 229 patients undergoing radiotherapy (RT) and assessed its association with progression-free survival and overall survival over six years. Patients were classified into two phenotypes based on post-RT changes in dodecanoic acid: The Increase Phenotype (IP) had lower baseline concentrations and showed a post-RT rise, whereas the Decrease Phenotype (DP) had higher pre-RT levels and declined after treatment. Dodecanoic acid levels were lower in tumors than in peritumoral samples, and their association with phenotypes varied by sampling region, suggesting that systemic changes reflect broader metabolic adaptations rather than local tissue concentrations. Post-RT increases in dodecanoic acid were associated with higher paraoxonase-1 activity, suggesting a link with antioxidant status. Patients in the IP group had a significantly lower risk of progression than those in the DP group, whereas no significant differences in overall survival were observed. These findings highlight the potential utility of dodecanoic acid measurement as a prognostic biomarker and suggest that modulating fatty acid metabolism could be explored as a therapeutic strategy.

17 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMauricio Murcia-Mejia
Mauricio Murcia-Mejia
MCMarta Canela Capdevila
Marta Canela Capdevila
RGRaquel García-Pablo
Raquel García-Pablo
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
JAJuan Manuel Jiménez Aguilar
Juan Manuel Jiménez Aguilar
Jorge JovenJorge Joven
Jorge Joven
Lung cancer is the leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for over 85% of cases and poor prognosis in advanced stages. This study explored shifts in circulating metabolite levels in NSCLC patients versus healthy controls and examined the effects of conventionally fractionated radiation therapy (CFRT) and stereotactic body radiation therapy (SBRT). We enrolled 91 NSCLC patients (38 CFRT and 53 SBRT) and 40 healthy controls. Plasma metabolite levels were assessed using semi-targeted metabolomics, revealing 32 elevated and 18 reduced metabolites in patients. Key discriminatory metabolites included ethylmalonic acid, maltose, 3-phosphoglyceric acid, taurine, glutamic acid, glycocolic acid, and d-arabinose, with a combined Receiver Operating Characteristics curve indicating perfect discrimination between patients and controls. CFRT and SBRT affected different metabolites, but both changes suggested a partial normalization of energy and amino acid metabolism pathways. In conclusion, metabolomics identified distinct metabolic signatures in NSCLC patients with potential as diagnostic biomarkers. The differing metabolic responses to CFRT and SBRT reflect their unique therapeutic impacts, underscoring the utility of this technique in enhancing NSCLC diagnosis and treatment monitoring.